Natera, Inc. $NTRA Stake Reduced by Allianz Asset Management GmbH

Allianz Asset Management GmbH decreased its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 2.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 201,533 shares of the medical research company’s stock after selling 4,816 shares during the period. Allianz Asset Management GmbH owned approximately 0.15% of Natera worth $32,441,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. Rakuten Investment Management Inc. purchased a new stake in shares of Natera during the third quarter worth $34,096,000. SWS Partners increased its position in Natera by 11.8% in the 3rd quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock worth $7,572,000 after purchasing an additional 4,980 shares during the last quarter. New York State Common Retirement Fund raised its stake in shares of Natera by 63.2% during the 3rd quarter. New York State Common Retirement Fund now owns 148,247 shares of the medical research company’s stock worth $23,863,000 after purchasing an additional 57,400 shares in the last quarter. Vontobel Holding Ltd. raised its stake in shares of Natera by 192.5% during the 3rd quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock worth $1,373,000 after purchasing an additional 5,614 shares in the last quarter. Finally, Baird Financial Group Inc. lifted its holdings in shares of Natera by 277.8% during the 2nd quarter. Baird Financial Group Inc. now owns 26,624 shares of the medical research company’s stock valued at $4,498,000 after buying an additional 19,576 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Regulatory/catalyst: Natera submitted a PMA to the FDA for Signatera CDx to detect minimal residual disease in bladder cancer after positive phase‑3 results — a potential pathway to a companion‑diagnostic revenue stream and better reimbursement/clinical adoption if approved. Natera files Signatera CDx PMA (Zacks)
• Neutral Sentiment: Routine insider trims: Several non‑executive insiders (e.g., Solomon Moshkevich, John Fesko) sold modest, single‑digit percentages of their positions; these look like routine liquidity actions but add incremental supply. InsiderTrades report on recent sales
• Negative Sentiment: Material CEO sale: CEO Steven Chapman sold 85,299 shares (~40% reduction) on Feb 2 for roughly $19.7M — a large, high‑visibility block that investors commonly view as a negative signal and that likely amplified downward pressure. CEO Form 4 (SEC)
• Negative Sentiment: Additional executive selling: CEO Chapman sold another 4,725 shares (Feb 3) and CFO Michael Burkes Brophy sold 6,939 shares (Feb 3), further trimming insider ownership and reinforcing near‑term selling pressure. CEO additional Form 4 CFO Form 4 (SEC)

Natera Price Performance

Natera stock opened at $197.08 on Friday. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36. The firm has a fifty day moving average price of $234.15 and a two-hundred day moving average price of $195.75. The firm has a market cap of $27.26 billion, a price-to-earnings ratio of -86.06 and a beta of 1.64.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. During the same quarter in the previous year, the firm posted ($0.26) earnings per share. The company’s revenue for the quarter was up 34.7% on a year-over-year basis. As a group, sell-side analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on NTRA shares. JPMorgan Chase & Co. raised their price objective on shares of Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Guggenheim raised their price target on shares of Natera from $230.00 to $270.00 and gave the company a “buy” rating in a report on Monday, January 5th. TD Cowen reaffirmed a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. BTIG Research increased their target price on shares of Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Finally, UBS Group boosted their price target on Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $249.20.

Insiders Place Their Bets

In other Natera news, insider John Fesko sold 3,594 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $231.02, for a total value of $830,285.88. Following the sale, the insider directly owned 178,081 shares in the company, valued at $41,140,272.62. This trade represents a 1.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Michael Burkes Brophy sold 6,939 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $227.83, for a total transaction of $1,580,912.37. Following the transaction, the chief financial officer owned 52,120 shares in the company, valued at approximately $11,874,499.60. The trade was a 11.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 455,899 shares of company stock valued at $106,475,440 over the last ninety days. 5.63% of the stock is owned by insiders.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.